These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32294093)

  • 1. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
    Dumas EK; Demiraslan H; Ingram RJ; Sparks RM; Muns E; Zamora A; Larabee J; Garman L; Ballard JD; Boons GJ; James JA; Kayabas U; Doganay M; Farris AD
    PLoS One; 2020; 15(4):e0230782. PubMed ID: 32294093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
    Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.
    Nguyen ML; Terzyan S; Ballard JD; James JA; Farris AD
    Infect Immun; 2009 Nov; 77(11):4714-23. PubMed ID: 19720758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
    Taft SC; Weiss AA
    Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.
    Crowe SR; Garman L; Engler RJ; Farris AD; Ballard JD; Harley JB; James JA
    Vaccine; 2011 May; 29(20):3670-8. PubMed ID: 21420416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
    Brenneman KE; Doganay M; Akmal A; Goldman S; Galloway DR; Mateczun AJ; Cross AS; Baillie LW
    FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.
    Dumas EK; Nguyen ML; Cox PM; Rodgers H; Peterson JL; James JA; Farris AD
    Vaccine; 2013 Apr; 31(14):1856-63. PubMed ID: 23415781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
    Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
    Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
    Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
    Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Welkos S; Little S; Friedlander A; Fritz D; Fellows P
    Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
    Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
    Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection.
    Vrentas CE; Moayeri M; Keefer AB; Greaney AJ; Tremblay J; O'Mard D; Leppla SH; Shoemaker CB
    J Biol Chem; 2016 Oct; 291(41):21596-21606. PubMed ID: 27539858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.
    Abboud N; Casadevall A
    Clin Vaccine Immunol; 2008 Jul; 15(7):1115-23. PubMed ID: 18480236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice].
    Wang X; Chi X; Liu J; Liu W; Liu S; Qiu S; Wen Z; Fan P; Liu K; Song X; Fu L; Zhang J; Yu C
    Sheng Wu Gong Cheng Xue Bao; 2016 Nov; 32(11):1590-1599. PubMed ID: 29034628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines.
    Laws TR; Kuchuloria T; Chitadze N; Little SF; Webster WM; Debes AK; Saginadze S; Tsertsvadze N; Chubinidze M; Rivard RG; Tsanava S; Dyson EH; Simpson AJ; Hepburn MJ; Trapaidze N
    PLoS One; 2016; 11(3):e0148713. PubMed ID: 27007118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.
    Glinert I; Bar-David E; Sittner A; Weiss S; Schlomovitz J; Ben-Shmuel A; Mechaly A; Altboum Z; Kobiler D; Levy H
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4878-85. PubMed ID: 27270276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
    Gaur R; Gupta PK; Banerjea AC; Singh Y
    Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
    Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
    [No Abstract]   [Full Text] [Related]  

  • 20. Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.
    Chi X; Li J; Liu W; Wang X; Yin K; Liu J; Zai X; Li L; Song X; Zhang J; Zhang X; Yin Y; Fu L; Xu J; Yu C; Chen W
    Clin Vaccine Immunol; 2015 May; 22(5):553-60. PubMed ID: 25787135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.